Response to mepolizumab treatment is sustained across 4-weekly dosing periods Source: ERJ Open Res, 6 (3) 00068-2020; 10.1183/23120541.00068-2020 Year: 2020
Characterising individual response to mepolizumab treatment Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007
Inhalations of ultra-low doses of alkylating drug for the treatment of steroid-dependant asthma: anti-inflammatory effect of therapy Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001
Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS) Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006
Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006
Efficacy of short-term high dose predonisolone therapy in acute exacerbation of bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001
Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy Source: Eur Respir J 2010; 36: 524-530 Year: 2010
Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Efficiency of pentoxifylline different doses in sarcoidosis treatment Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008
Real-world treatment patterns of mepolizumab therapy in Canada Source: Virtual Congress 2020 – Management of chronic lung conditions Year: 2020
Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma Source: Annual Congress 2010 - Allergy and risk factors in paediatrics Year: 2010
Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011
Immunomodulating activity of inhalations of ultra-low doses of alkylating drug melphalan for severe bronchial asthma treatment Source: Eur Respir J 2004; 24: Suppl. 48, 580s Year: 2004
New method of treatment of steroid-dependant asthma with inhalations of ultra-low doses of alkylating drug: clinical results Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001